Florida Cancer Specialists & Research Institute Leaders Serve on Faculty for Value-Based Cancer Care Summit
October 19, 2022 14:00 ET
|
Florida Cancer Specialists & Research Institute
Fort Myers, Fla., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Fort Myers, Fla., October 19, 2022 – Senior leaders of Florida Cancer Specialists & Research Institute (FCS) will serve on the faculty for...
Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
October 18, 2022 08:00 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the U.S. Food and...
Global Oncology Nutrition Market Report 2022: A $2.13 Billion Market in 2026 Featuring B. Braun Melsungen, Danone India, Abbott Laboratories, Nestle, Victus
October 06, 2022 06:13 ET
|
Research and Markets
Dublin, Oct. 06, 2022 (GLOBE NEWSWIRE) -- The "Oncology Nutrition Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.The global oncology nutrition market is...
Science Crossing Borders: Celebrating the Contributions of Immigrant Scientists
October 05, 2022 09:45 ET
|
The Vilcek Foundation
NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- They come from around the world—born in Taiwan, India, Lebanon, Israel, Romania, and Russia, among other places—but they all call the United States home....
Global Cell Culture Market to Surpass US$ 33,452.8 Million by 2030, Says Coherent Market Insights (CMI)
September 29, 2022 09:15 ET
|
CMI
Seattle, Sept. 29, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global cell culture market is estimated to be valued at US$ 19,198.0 million in 2022 and is expected to exhibit...
Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma During Phase 3 Trial, a Joint Program With Hengrui Pharma
September 10, 2022 04:00 ET
|
Elevar Therapeutics
Top-line findings were presented today at the annual European Society for Medical Oncology (ESMO) Congress This is the first positive pivotal trial to show survival benefits with a PD-1 inhibitor...
Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma During Phase 3 Trial, a Joint Program With Hengrui Pharma
September 07, 2022 18:05 ET
|
Elevar Therapeutics
Top-line findings will be presented Sept. 10 at the annual European Society for Medical Oncology (ESMO) Congress This is the first positive pivotal trial to show survival benefits with a PD-1...
Elevar Therapeutics Announces Data From Phase 3 Study of Rivoceranib in Combination With Camrelizumab Is Accepted for Late-Breaking Proffered Paper Presentation at ESMO Congress 2022
August 25, 2022 07:00 ET
|
Elevar Therapeutics
SALT LAKE CITY, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...
Global Culture Media Market Anticipated to Generate a Revenue of $5,398.6 Million and Rise at a CGAR of 7.7% over the Analysis Timeframe 2020-2027 [230-Pages] | Research Dive
August 22, 2022 09:07 ET
|
Research Dive
New York, USA, Aug. 22, 2022 (GLOBE NEWSWIRE) -- According to a report published by Research Dive, the global culture media market is envisioned to generate a revenue of $5,398.6 million and grow at...
Cell Culture Reagents Market Worth $11.04 billion by 2029 - Exclusive Report by Meticulous Research®
August 08, 2022 11:00 ET
|
Meticulous Market Research Pvt. Ltd.
Redding, California, Aug. 08, 2022 (GLOBE NEWSWIRE) -- According to a new market research report, ‘Cell Culture Reagents Market by Product (Growth Factors and Cytokines, Supplements,...